Current Research
MAJOR RESEARCH INTERESTS:
My current research focus is on Translation Science, which includes biomarker development for clinical trials, immunotherapy in gynecologic cancer, developmental therapeutics, personalized medicine, and targeted therapy – (ie.Wnt pathway, PARP inhibition). Ultimately, I would like to use the preclinical data generated in my lab to drive development of new clinical trials.
CURRENT CLINICAL RESEARCH PROJECTS
- EAE 161: Perfusion CT to Predict Progression-Free Survival and Response Rate in Bevacizumab and Paclitaxel Treatment of Platinum-Resistant Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma (Role: Site PI).
- UAB 1879: Phase 2 Multicohort Study to Evaluate the Safety and Efficacy of Novel Treatment Combinations in Patients with Recurrent Ovarian Cancer (OPAL) (Role: Site PI).
- UAB 1788: Pilot Study of Daily Exemestane in Women with Complex Atypical Hyperplasia of the Endometrium / Endometrial Intraepithelial Neoplasia or Low 3Grade Endometrial Cancer (Role: Site PI).
- UAB 1861: An Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination with Paclitaxel to Assess Safety, Tolerability, and Pharmacokinetics in Patients with Advanced or Metastatic Solid Tumors (Role: Site PI).
- UAB 17105: A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients with Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer (Role: National PI).
- UAB 1921: Cabozantinib plus Nivolumab and Ipilimumab in patients with recurrent Gynecologic Carcinosarcoma (Investigator Initiated Trial; Role: National PI).
- UAB 1801: Phase 1 trial of CB-839 in Combination with Niraparib in platinum resistant BRCA-wild type Ovarian Cancer Patients (Investigator Initiated Trial; Role: National PI).
- UAB 1885: Phase 1 Trial of M4344 and Niraparib in patients with PARP resistant recurrent ovarian cancer (Investigator Initiated Trial; Role: National PI).
- UAB 18107: A Phase 2, Single Arm Study of Atezolizumab + Bevacizumab in women with advanced, recurrent or persistent endometrial cancer (Role: Co-PI).
- UAB 1935: The OVAL Study: A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Orangemen Badinage (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer (Role: National Co-PI).
- UAB 1983: A Randomized Phase 3, Double-Blind Study of Chemotherapy with or Without Pembrolizumab Followed by Maintenance with Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001 / ENGOT-ov43) (Role: National Co-PI).
- UAB 1977: A Phase Ib, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (Role: Site PI).
RESEARCH SUPPORT:
Current
1. GOG Foundation Scholar Investigator Award
Dates: 7/2019-6/2024
Amount: $136,275 (Arend, PI)
2. NCCN YIA Award: The role of TGF-B in immune suppression in suboptimally debulked ovarian cancer patients
Dates: 07/01/2018 – 06/30/2020
Amount: $75,000 (Arend, PI)
3. Task Order Request for Proposal (TORLFP) Grant sponsored by the NCI/Division of Prevention, Pilot Study of Daily Exemestane In Women with Complex Atypical Hyperplasia of the Endometrium or Low-Grade Endometrial Cancer
Dates: 01/01/2016 – 01/01/2020
Amount: $23,188 (Arend, Sub Investigator)
4. NIH Loan Repayment Program Award
Dates:10/01/2016 – 10/01/2020
Amount: $150,000 (Arend, PI)
5. DOD Early Career Investigator Grant
Dates: 7/1/2018 – 2/1/2022
Amount: $1,076,624 (Arend, PI)
6. DOD Nested Young Investigator Award
Dates: 5/1/2018 – 4/1/2022
Amount: $840,782 (Birrer, PI) (Arend, Co-Investigator)
7. UAB School of Medicine AMC21 Multi-PI Grant
Dates: 1/2018 – 12/2020
Amount: $300,000 (Troy D. Randall, Donald J. Buchsbaum, Rebecca Arend, Co-PIs)
8. R01 CA225177 NIH/NCI
Dates: 04/01/19 – 03/31/24
Amount: $213,000 (PI: Bellis) (Arend, Co- Investigator)
9. A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients with Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer
Dates: 12/21/2017 – 12/20/2022
Amount: $588,993 (Arend, National PI)
10. Investigator Initiated Trial: Phase 1 Trial of M4344 and Niraparib in patients with PARP resistant recurrent ovarian cancer
Dates: 04/08/2019 – 04/07/2024
Amount: $588,729 (Arend, PI)
11. Investigator Initiated Trial: Cabozantinib plus Nivolumab and Ipilimumab patients with recurrent Gynecologic Carcinosarcoma (uterine, vaginal, ovarian)
Dates: 04/05/2019 – 04/04/2024
Amount: $750,473.25 (Arend, PI)
12. Investigator Initiated Trial: A Phase 2, Single Arm Study of Atezolizumab + Bevacizumab in Women with Advanced, Recurrent or Persistent Endometrial Cancer
Dates: 07/20/2019 – 07/19/2024
Amount: $702,255 (Arend, Co-PI)
13. Investigator Initiated Trial: A phase 1 trial of CB-839 in Combination with Niraparib in platinum resistant BRCA-wild type Ovarian Cancer Patients
Dates: 06/24/2019 – 06/23/2024
Amount: $881,224.72 (Arend, PI)
14. GCS Foundation Grant: Investigating Immunotherapy Biomarkers for Carcinosarcoma
Dates: 05/01/2020 – 05/01/2022
Amount: $170,000
Completed
1. U10 NIH Grant Neoadjuvant Chemotherapy Tumor Profiling in Ovarian Cancer: Genomic and Proteomic Analysis
Dates: 04/28/2014 – 04/28/2019 (Arend, Sub Investigator)
2. Faculty Development Grant
Dates: 7/10/17 – 7/10/18
Amount: $50,000 (Klug, Co-PI) (Arend, Co-PI)
3. Center for Genomic Medicine (CGM) Pilot Grant
Dates: 10/1/2017 – 10/1/2018
Amount: $75,000 (Yang, PI) (Arend, Co-Investigator)
4. ACS-IRG Junior Faculty Development Grant
Dates: 03/01/2016 – 12/31/2018
Amount: $40,000 (Arend, PI)
5. NCTN-LAPS Program Translational Research Initiative
Dates: 08/01/2015 – 08/01/2016
Amount: $20,000 (Arend, Co-Investigator)
6. Foundation for Women’s Cancer Research Grant (WeRoc/OChO Ovarian Cancer Research Grant)
Dates: 04/01/2014 – 05/01/2015
Amount: $50,000 (Arend, PI)
7. Norma Livingston Ovarian Cancer Research Grant
Dates: 06/01/2014 – 06/01/2015
Amount: $75,000 (Arend, PI)
8. Norma Livingston Ovarian Cancer Research Grant
Dates: 07/01/2015 – 07/01/2019
Amount: $100,000 (Arend, PI)
9. Breast Cancer Research Foundation Award
Dates: 07/01/2013 – 07/2015 (Arend, Co-Investigator)
10. NIH NRSA T-32 Training grant; Grant # T32CA091078
Dates: 07/01/2013 – 07/01/2014
11. UAB Center for Clinical and Translational Science Multidisciplinary Partner Network Pilot Program
Dates: 04/1/2016 – 04/30/2017
Amount $60,000 (Arend, PI)
12. CCC Translational Research Initiative Grant, RNA polymerase I in ovarian cancer
Dates: 08/01/2016 – 08/01/2017
Amount: $20,000 (Arend, Co-PI)
13. Glycosylation-Dependent Mechanisms Regulating Ovarian Tumor Cell Survival; RO1 Grant
Dates: 04/01/2015 – 09/01/2017
Amount: $279,300 (Arend, Co-Investigator)
14. UAB NCTN LAPS Young Investigator Mentoring Program
Dates: 11/05/2015 – 11/05/2017
Amount: $4,000 (Arend, PI)
15. Ovarian Early Detection Cancer Research Grant
Foundation for Women’s Cancer
Dates: 04/01/2016 – 02/28/2018
Amount: $25,000 (Arend, PI)
16. Wilma Williams Education and Clinical Research Grant for Endometrial Cancer
SGO/Foundation for Women’s Cancer
Dates: 01/01/2016 – 12/31/2017
Amount: $10,000 (Arend, PI)
17. American Institute for Cancer Research
Dates: 01/01/2015 – 12/31/2017
Amount: $150,000 TDC (Arend, Sub Investigator) (Gower, PI)
18. ABOG/AAOGF Scholarship Award
Dates:07/01/2015 – 07/01/2018
Amount: $360,000 (Arend, PI)
19. CCC Faculty Development Pilot Grant
Dates: 08/01/2017 – 08/01/2018 (Yoon, PI) (Arend, Co-PI)
20. DNA methylation patterns in the immune system of ovarian cancer patients
Laura Crandall Brown Foundation Grant
Dates: 11/01/2015 – 11/01/2019
Amount: $50,000 (Arend, Co-PI)
21. Personalized Medicine Project in Recurrent Ovarian Cancer Patients
UAB – Personalized Medicine Institute
Dates: 09/01/2015 – 09/01/2019
Amount: $150,000 (Arend, PI)
22. CCC Young Investigator Award
Dates: 7/16/2018 – 7/15/2019
Amount: $50,000 (Arend, Co-PI)
